| WH Quiz 1 |
WH Quiz 1 |
Unfinished |
2020-12-07 |
jav5046 |
31 |
0 |
edit |
|
| Peds Genetics |
Peds Genetics |
Unfinished |
2020-11-03 |
jav5046 |
57 |
0 |
edit |
|
| Peds Eating D/O |
Peds Eating D/O |
Unfinished |
2020-11-03 |
jav5046 |
98 |
0 |
edit |
|
| Peds Respiratory D/O |
Peds Respiratory D/O |
Unfinished |
2020-11-08 |
jav5046 |
64 |
0 |
edit |
|
| Adolescent Mental |
Adolescent Mental |
Unfinished |
2020-11-03 |
jav5046 |
32 |
0 |
edit |
|
| Peds Psych d/o |
Peds Psych d/o |
Unfinished |
2020-11-03 |
jav5046 |
91 |
0 |
edit |
|
| Peds ABD pain |
Peds ABD pain |
Unfinished |
2020-11-03 |
jav5046 |
38 |
0 |
edit |
|
| Peds Heme |
Peds Heme |
Unfinished |
2020-11-03 |
jav5046 |
125 |
0 |
edit |
|
| Peds Trauma |
Peds Trauma |
Unfinished |
2020-11-03 |
jav5046 |
87 |
0 |
edit |
|
| Peds MSK D/O |
Peds MSK D/O |
Unfinished |
2020-11-03 |
jav5046 |
159 |
0 |
edit |
|
| Peds Airway D/O |
Peds Airway D/O |
Unfinished |
2022-07-04 |
jav5046 |
132 |
1 |
edit |
|
| Peds CV |
Peds CV |
Unfinished |
2020-11-09 |
jav5046 |
178 |
0 |
edit |
|
| Peds GU/GYN |
Peds GU/GYN |
Unfinished |
2020-11-04 |
jav5046 |
193 |
0 |
edit |
|
| Peds Derm |
Peds Derm |
Unfinished |
2020-11-12 |
jav5046 |
162 |
0 |
edit |
|
| Peds GI D/O |
Peds D/O |
Unfinished |
2020-11-12 |
jav5046 |
209 |
0 |
edit |
|
| Peds Endocrine |
Peds Endocrine |
Unfinished |
2020-11-05 |
jav5046 |
184 |
0 |
edit |
|
| WH Quiz 2 |
WH Quiz 2 |
Unfinished |
2020-12-06 |
jav5046 |
33 |
0 |
edit |
|
| WH Quiz 3 |
WH Quiz 3 |
Unfinished |
2020-12-06 |
jav5046 |
35 |
0 |
edit |
|
| WH Quiz 4 |
WH Quiz 4 |
Unfinished |
2020-12-06 |
jav5046 |
25 |
0 |
edit |
|
| WH Quiz 5 |
WH Quiz 5 |
Unfinished |
2020-12-06 |
jav5046 |
25 |
0 |
edit |
|
| WH Quiz 6 |
WH Quiz 6 |
Unfinished |
2020-12-06 |
jav5046 |
37 |
0 |
edit |
|
| Antipsychotics |
Therapeutic Mechanis |
Unfinished |
2022-06-11 |
jav5046 |
4 |
0 |
edit |
|
| Antipsychotics |
Mesolimbic/Mesostriatal Dopamine Pathway and D2 Antagonists |
Unfinished |
2022-06-11 |
jav5046 |
5 |
0 |
edit |
|
| Antipsychotics |
Mesocortical dopamine pathway and D2 Antagonists |
Unfinished |
2022-06-11 |
jav5046 |
5 |
0 |
edit |
|
| Antipsychotics |
Tuberoinfundibular Dopamine Pathway and D2 Antagonists |
Unfinished |
2022-06-11 |
jav5046 |
3 |
0 |
edit |
|
| Antipsychotics |
Nigrostriatal Dopamine Pathway and D2 Antagonists |
Unfinished |
2022-06-11 |
jav5046 |
5 |
0 |
edit |
|
| Antipsychotics |
Reciprocal Relationship of Dopamine and Acetylcholine |
Unfinished |
2022-06-11 |
jav5046 |
6 |
0 |
edit |
|
| Antipsychotics |
Drug-Induced Acute Dystonia |
Unfinished |
2022-06-11 |
jav5046 |
2 |
0 |
edit |
|
| Antipsychotics |
Akathisia |
Unfinished |
2022-06-11 |
jav5046 |
6 |
0 |
edit |
|
| Antipsychotics |
Tardive Dyskinesia |
Unfinished |
2022-06-11 |
jav5046 |
10 |
0 |
edit |
|
| Antipsychotics |
Treatment of Tardive Dyskinesia |
Unfinished |
2022-06-11 |
jav5046 |
5 |
0 |
edit |
|
| Antipsychotics |
Drugs Targeting 5HT2A Receptors W/&w/o Simultaneously Targeting D2 Receptors |
Unfinished |
2022-06-11 |
jav5046 |
3 |
0 |
edit |
|
| Antipsychotics |
5HT2A Receptor Regulation of Downstream DA Release |
Unfinished |
2022-06-11 |
jav5046 |
4 |
0 |
edit |
|
| Antipsychotics |
5HT2A Receptor Antagonism and Downstream DA Release |
Unfinished |
2022-06-11 |
jav5046 |
7 |
0 |
edit |
|
| Antipsychotics |
How do 5HT2A Antagonist Actions Reduce Hyperprolactinemia |
Unfinished |
2022-06-11 |
jav5046 |
8 |
0 |
edit |
|
| Antipsychotics |
Drugs Targeting 5HT1A Receptors and D2 Receptors as Partial Agonists |
Unfinished |
2022-06-11 |
jav5046 |
7 |
0 |
edit |
|
| Antipsychotics |
5HT1A Receptor Partial Agonist and Downstream DA Release |
Unfinished |
2022-06-11 |
jav5046 |
5 |
0 |
edit |
|
| Antipsychotics |
Links B/w Receptor Binding Properties & Other Therapeutic Actions & Side Effects |
Unfinished |
2022-06-11 |
jav5046 |
8 |
0 |
edit |
|
| Antipsychotics |
Cardiometabolic Actions |
Unfinished |
2022-06-11 |
jav5046 |
4 |
0 |
edit |
|
| Antipsychotics |
Metabolic Monitoring Tool Kit |
Unfinished |
2022-06-11 |
jav5046 |
9 |
0 |
edit |
|
| Psychosis |
Schizophrenia |
Unfinished |
2022-06-11 |
jav5046 |
6 |
0 |
edit |
|
| Psychosis |
Dimensions of Schizophrenia |
Unfinished |
2022-06-11 |
jav5046 |
7 |
0 |
edit |
|
| Psychosis |
NMDA Schizophrenia |
Unfinished |
2022-06-11 |
jav5046 |
28 |
0 |
edit |
|
| Psychosis |
Dopamine |
Unfinished |
2022-06-11 |
jav5046 |
31 |
0 |
edit |
|
| Atypical and Typical |
Antipsychotics |
Unfinished |
2022-06-11 |
jav5046 |
20 |
0 |
edit |
|
| Depression |
Depression (Mood D/O) |
Unfinished |
2022-06-13 |
jav5046 |
20 |
0 |
edit |
|
| Quiz 2 |
Quiz 2 |
Unfinished |
2022-06-13 |
jav5046 |
22 |
0 |
edit |
|
| A/TTx |
A/TTx |
Unfinished |
2022-06-13 |
jav5046 |
24 |
0 |
edit |
|
| Management |
SSRIs |
Unfinished |
2023-02-02 |
jav5046 |
54 |
0 |
edit |
|
| Midterm |
Management |
Unfinished |
2023-03-01 |
jav5046 |
14 |
0 |
edit |
|